These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 12053416)

  • 1. National Institute for Clinical Excellence (NICE). HTA rhyme and reason?
    Taylor R
    Int J Technol Assess Health Care; 2002; 18(2):166-70. PubMed ID: 12053416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health technology assessment in England and Wales.
    Stevens A; Milne R
    Int J Technol Assess Health Care; 2004; 20(1):11-24. PubMed ID: 15176173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health technology assessment for the NHS in England and Wales.
    Woods K
    Int J Technol Assess Health Care; 2002; 18(2):161-5. PubMed ID: 12053415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence and quality, practicalities and judgments: some experience from NICE.
    Culyer A; Rawlins M
    Healthc Q; 2012; 15 Spec No():66-9. PubMed ID: 24863122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HTA'd in the USA: A Comparison of ICER in the United States with NICE in England and Wales.
    Thokala P; Carlson JJ; Drummond M
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1162-1170. PubMed ID: 32857653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opportunity costs and local health service spending decisions: a qualitative study from Wales.
    Karlsberg Schaffer S; Sussex J; Hughes D; Devlin N
    BMC Health Serv Res; 2016 Mar; 16():103. PubMed ID: 27012523
    [TBL] [Abstract]